Rabbit B Cell Culture for Rapid Antibody Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ex vivo B cell cultures, particularly those using human, murine, and llama B cells, have a doubling time of 25-36 hours, which is too long for efficient production of monoclonal antibodies, especially in therapeutic applications where rapid production is crucial for personalized cancer therapies.
Innovation Solution
Using rabbit B cells with induced or maintained expression of Bcl-6 and an anti-apoptotic nucleic acid molecule, such as Bcl-xL, to achieve a doubling time of 20 hours or less, allowing for faster and higher antibody production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If human, murine, or llama B cells are used for ex vivo antibody production, then the cells can be cultured with Bcl-6 and anti-apoptotic nucleic acid expression, but the doubling time remains 25-36 hours which is too long for efficient therapeutic production
Solution Approach 1:
The patent changes the species parameter from human/murine/llama B cells to rabbit B cells, which naturally exhibit a shorter doubling time (20 hours or less) compared to traditional B cell sources (25-36 hours). This parameter change in cell source species directly improves antibody production speed while maintaining the ability to culture cells ex vivo with appropriate molecular expression
2Reliability
If conventional B cell cultures with 25-36 hour doubling time are used, then the culture method is established and reliable, but the time to produce sufficient antibody concentration extends to 15-20 days
Solution Approach 1:
By changing the cell source parameter to rabbit B cells, the patent achieves a shorter doubling time (20 hours or less) while maintaining culture reliability through the same molecular expression strategy (Bcl-6 and anti-apoptotic nucleic acid). This reduces the time to reach sufficient antibody concentration from 15-20 days to 9-12 days, preserving reliability while improving speed
3Productivity
If rabbit B cells are used with induced Bcl-6 and anti-apoptotic nucleic acid expression, then the doubling time is reduced to 20 hours or less, but this represents a deviation from conventional cell sources
Solution Approach 1:
The patent changes the species parameter to rabbit B cells, which naturally have faster proliferation kinetics. While this introduces a new cell source, the molecular manipulation strategy (Bcl-6 and anti-apoptotic nucleic acid expression) remains the same, making the transition manageable. The productivity gain (doubling time ≤20 hours vs. 25-36 hours) outweighs the complexity of establishing a new cell source protocol
Data Source
AI summary
The present invention provides means and methods for producing improved ex vivo B cell cultures with a short doubling time.